Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 8/2010

01-08-2010 | Original Article—Liver, Pancreas, and Biliary Tract

CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma

Authors: Mitsuo Shimada, Koji Sugimoto, Shuichi Iwahashi, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto

Published in: Journal of Gastroenterology | Issue 8/2010

Login to get access

Abstract

Background and aim

CD133 is one of the most important cancer-initiating (stem) cell markers and was confirmed to be expressed in solid cancers such as colon cancer. However, no one has investigated the role of CD133 in intrahepatic cholangiocarcinoma (IHCC). The aim of this study was to clarify the clinical role of CD133 expression in IHCC.

Patients and methods

Twenty-nine patients with IHCC who underwent hepatic resection at our institution were enrolled in this study. Expression of CD133 was examined using anti-CD133 antibody. Staining was observed in the cytoplasm of cancer cells and CD133-positive cells distributed in the whole tumor. The patients were divided into two groups: the CD133-positive group (n = 14) and CD133-negative group (n = 15), in which no staining of CD133 was observed. Clinicopathological factors including hypoxia-inducible factor-1α expression were compared between the two groups. The prognostic factors were investigated by multivariate analysis using Cox’s proportional hazard model.

Results

The 5-year survival rate in the CD133-positive group (8.0%) was worse than that in the CD133-negative group (57.0%). In the CD133-positive group, the incidence of intrahepatic metastasis and positive expression of hypoxia-inducible factor-1α tended to be higher than that in the CD133 negative group. The multivariate analysis revealed CD133 expression was an independent prognostic indicator in IHCC.

Conclusions

CD133 expression tended to be related to higher incidences of intrahepatic metastasis and positive expression of hypoxia-inducible factor-1α; furthermore, it was independently related to worse prognosis. Therefore, the CD133 expression is a potential prognostic indicator in IHCC.
Literature
1.
Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, et al. The liver cancer study group of Japan report of the 16th follow-up survey of primary liver cancer. Hepatol Res. 2005;32:163–72.CrossRefPubMed
2.
Yamamoto M, Ariizumi S. Intrahepatic recurrence after surgery in patients with intrahepatic cholangiocarcinoma. J Gastroenterol. 2006;2006(41):925–6.CrossRef
3.
Thelen A, Scholz A, Benckert C, Schröder M, Weichert W, Wiedenmann B, et al. Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. J Gastroenterol. 2008;43:959–66.CrossRefPubMed
4.
Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41:893–900.CrossRefPubMed
5.
Kobayashi A, Miwa S, Nakata T, Miyagawa S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 2010;97:56–64.CrossRefPubMed
6.
Shimada M, Yamashita Y, Aishima S, Shirabe K, Takenaka K, Sugimachi K. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001;88:1463–6.CrossRefPubMed
7.
O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.CrossRefPubMed
8.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.CrossRefPubMed
9.
Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Jauberteau MO. Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol. 2009;34:717–27.PubMed
10.
Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:8205–12.CrossRefPubMed
11.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.CrossRefPubMed
12.
Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 2007;67:3153–61.CrossRefPubMed
13.
Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120:1444–50.CrossRefPubMed
14.
Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008;98:1389–97.CrossRefPubMed
15.
Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285–9.CrossRefPubMed
16.
Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 2009;69:7160–4.CrossRefPubMed
17.
Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha. Oncogene. 2009;28:3949–59.CrossRefPubMed
18.
Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99:100–9.CrossRefPubMed
19.
Kanamoto M, Yoshizumi T, Ikegami T, Imura S, Morine Y, Ikemoto T, et al. Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver: a case report. J Med Investig. 2008;55:161–5.CrossRef
20.
Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–56.CrossRefPubMed
21.
Liver Cancer Study Group of Japan. Classification of primary liver cancer. 1st English ed. Tokyo: Kanehara; 1997.
22.
Becker L, Huang Q, Mashimo H. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. ScientificWorldJournal. 2008;8:1168–76.CrossRefPubMed
23.
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–23.CrossRefPubMed
24.
Batmunkh E, Shimada M, Morine Y, Imura S, Kanemura H, Arakawa Y, et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1α) in patients with the gallbladder carcinoma. Int J Clin Oncol. 2010;15(1):59–64.CrossRefPubMed
25.
Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1a and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res. 2006;12:5112–7.CrossRefPubMed
26.
Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1–9.CrossRefPubMed
27.
Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212–8.CrossRefPubMed
Metadata
Title
CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma
Authors
Mitsuo Shimada
Koji Sugimoto
Shuichi Iwahashi
Tohru Utsunomiya
Yuji Morine
Satoru Imura
Tetsuya Ikemoto
Publication date
01-08-2010
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-010-0235-3

Other articles of this Issue 8/2010

Journal of Gastroenterology 8/2010 Go to the issue

Original Article—Alimentary Tract

Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer

Original Article—Liver, Pancreas, and Biliary Tract

Diagnostic efficacy of the cell block method in comparison with smear cytology of tissue samples obtained by endoscopic ultrasound-guided fine-needle aspiration

Original Article—Alimentary Tract

Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States

Review

Autoimmune pancreatitis: the clinicopathological characteristics of the subtype with granulocytic epithelial lesions

Review

Gastroesophageal reflux disease

Original Article—Liver, Pancreas, and Biliary Tract

Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits